

# Contents

<b>Preface</b>	<b>xiii</b>
<b>1 Introduction</b>	<b>1</b>
<b>2 History, Definition, and Diagnosis of the Metabolic Syndrome</b>	<b>4</b>
Historical Aspects of the Metabolic Syndrome	4
Definition and Diagnosis of the Metabolic Syndrome Suggested by Various Groups and Associations	5
<b>3 Insulin Resistance in the Metabolic Syndrome</b>	<b>13</b>
Is Insulin Resistance Responsible for the Metabolic Syndrome?	13
Exercise and Insulin Resistance	14
Anti-inflammatory Nature of Exercise	15
<b>4 Is It Necessary to Redefine the Metabolic Syndrome?</b>	<b>22</b>
Criteria	23
<b>5 Is Insulin Resistance a Disorder of the Brain?</b>	<b>26</b>
Parasympathetic and Sympathetic Tones and Insulin Resistance	26
Hypothalamo-pituitary-adrenal Pathway and Parasympathetic and Sympathetic System, and GLUT-4 and Hypothalamic Neuropeptide Y in Insulin Resistance, Obesity, and the Metabolic Syndrome	27
Interaction(s) among NPY, Leptin, GLUT-4, Melanocortin, and Insulin and Its Relevance to Obesity, Insulin Resistance, and the Metabolic Syndrome	29
Insulin and Brain	31
Insulin and Brain Monoamines	34
Obesity and Basal Energy Expenditure	39
<b>6 Obesity</b>	<b>43</b>
Definition of Obesity	44
Incidence and Prevalence of Obesity	44
Obesity Could Run in the Family	45
Growth of Fast Food Industry and Obesity	45
Why Is Obesity Harmful?	46
Genetics of Obesity	47
Gene Expression Profile in Obesity	49

Biochemical and Functional Differences between Adipose Cells of Different Regions	49
Intramyocellular Lipid Content and Insulin Resistance	51
Intramyocellular Lipid Droplets and Insulin Resistance	53
Intramyocellular Lipid Droplets, Insulin Resistance, Perilipins, and HSL	54
Perilipins in Humans	55
Factors Regulating the Expression and Action of Perilipin	56
Perilipins and Inflammation	59
Low-grade Systemic Inflammation Occurs in Obesity	59
What Causes Abdominal Obesity?	61
11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 (11 $\beta$ -HSD-1) Enzyme and Obesity	61
Glucocorticoids and Perilipins	63
Glucocorticoids, TNF- $\alpha$ , and Inflammation	64
Perilipins, 11 $\beta$ -HSD-1, and Abdominal Obesity and the Metabolic Syndrome in High-Risk Groups Such as South Asians	65
<b>7 Perinatal Nutrition and Obesity</b>	<b>74</b>
Appetite Regulatory Centers Develop during the Perinatal Period	74
Ventromedial Hypothalamus Plays a Significant Role in the Development of Obesity, Type 2 Diabetes Mellitus, and the Metabolic Syndrome	76
Glucokinase in Hypothalamic Neurons and VMH Lesion in Goto-Kakizaki Rats and Their Relationship to Obesity, Type 2 Diabetes Mellitus, and the Metabolic Syndrome	77
Insulin and Insulin Receptors in the Brain and Their Role in the Pathobiology of Obesity, Type 2 Diabetes Mellitus, and the Metabolic Syndrome	78
NPY, Insulin, and Nitric Oxide in Obesity, Type 2 Diabetes Mellitus, and the Metabolic Syndrome	80
Insulin, Endothelial Nitric Oxide, and Metabolic Syndrome	81
Perinatal Programming of Adult Diseases	81
Fetal Nutrition Influences the Developing Neuroendocrine Hypothalamus	82
<b>8 Essential Hypertension</b>	<b>86</b>
Prevalence and Incidence of Hypertension	86
Free Radicals in the Pathobiology of Hypertension	88
Increase in Superoxide Anion Production in Hypertension: How and Why?	89
Mechanism(s) of Induction of Hypertension by Superoxide Anion	91
Role of NO in Hypertension	92
Salt, Cyclosporine, and Calcium Modulate O <sub>2</sub> <sup>-</sup> and Endothelial NO Generation	94
L-Arginine, NO, and Asymmetrical Dimethylarginine in Hypertension and Pre-eclampsia	95
Antihypertensive Drugs Suppress Superoxide Anion and Enhance NO Generation	97
Transforming Growth Factor- $\beta$ , NO, and Hypertension	97

<b>9 Dietary Factors and Hypertension</b>	<b>105</b>
Carbohydrate-rich and High-fat Diet and Hypertension	105
Fructose-induced Hypertension and Insulin Resistance and Its Modulation by Dietary Salt	106
Energy-dense Diet, Salt, and Hypertension	106
Diet-induced Hypertension, Renin-Angiotensin-Aldosterone System, and Nitric Oxide	107
High-sugar and High-fat-induced Hypertension and Reactive Oxygen Species and Nitric Oxide	108
High-fructose and Salt-induced Hypertension and Insulin Resistance	109
High-fat and High-carbohydrate-induced Hypertension and Sympathetic Nervous Activity	111
<b>10 Is Hypertension a Disorder of the Brain?</b>	<b>113</b>
NO Synthase (NOS) Activity in the Brain, Kidney, and Endothelium and Its Relationship to Hypertension	114
Reduced Hypothalamic NOS Produces Hypertension without Altering Hypothalamic Blood Flow	115
Hypothalamic NO Regulates Sympathetic Outflow	116
Steroid-induced Hypertension and Hypothalamus	117
Exercise Enhances Hypothalamic NOS Activity	119
Both Hypertension and Type 2 Diabetes Mellitus and Hence the Metabolic Syndrome Are Disorders of the Brain	119
<b>11 Type 2 Diabetes Mellitus</b>	<b>122</b>
Type 1 Diabetes Mellitus	122
Pathobiology of Type 1 Diabetes	123
Type 2 Diabetes Mellitus	125
Diagnostic Criteria for DM	126
Impaired Glucose Tolerance and Impaired Fasting Glucose	127
Definition of Gestational Diabetes Mellitus	127
Diagnostic Criteria for GDM	127
<b>12 Pathophysiology of Type 2 Diabetes Mellitus with Particular Reference to Hypothalamus</b>	<b>130</b>
Type 2 Diabetes Mellitus as a Disorder of the Brain	130
Liver Communicates with the Brain through the Vagus	131
Liver and Pancreatic $\beta$ Cells Communicate with Each Other through the Vagus	132
The Gut-brain-liver Axis Is Activated by Long-chain Fatty Acids (LCFAs or LCPUFAs)	132
BDNF and Obesity	136
BDNF and Type 2 Diabetes Mellitus in Humans	137
Insulin, Melanocortin, and BDNF	138
Ghrelin, Leptin, and BDNF	138
Low-grade Systemic Inflammation Occurs in Obesity and Type 2 Diabetes Mellitus	140
BDNF and Inflammation	141

<b>13</b>	<b>Insulin and Insulin Receptors in the Brain and Their Role in the Pathogenesis of Obesity and Type 2 Diabetes Mellitus</b>	<b>146</b>
	Insulin and Insulin Receptors in the Brain	146
	Glucose Transporters and Glucokinase in Hypothalamus	147
	Neuron-specific Disruption of the Insulin Receptor Gene (NIRKO)	147
	Insulin and Hypothalamic Neuropeptides	148
	Leptin Receptors on Pancreatic $\beta$ Cells	148
	Glucagon-like Peptide, Insulin, and the Metabolic Syndrome	149
<b>14</b>	<b>Insulin, Endothelial Nitric Oxide, and the Metabolic Syndrome</b>	<b>156</b>
	Insulin Resistance and Nitric Oxide	156
	Ghrelin Improves Endothelial Function in the Metabolic Syndrome	159
	Cross-talk between Insulin and Renin-Angiotensin-Aldosterone System	159
	Pro-inflammatory Cytokines Produce Insulin Resistance	161
<b>15</b>	<b>Obesity, Type 2 Diabetes Mellitus, the Metabolic Syndrome, and the Gut Microbiota</b>	<b>167</b>
	Gut Flora, Diet, Obesity, and Inflammation	167
	Germ-free Mice Are Resistant to Obesity	168
	Enteroendocrine Cell Expression of Gpr41 and Obesity	169
	Low-grade Systemic Inflammation, Diet, and Obesity	171
	Gastric Bypass Surgery for Obesity and the Metabolic Syndrome	171
	Diet, Gut, Liver, Adipose Tissue, and Hypothalamus in Obesity and the Metabolic Syndrome	173
<b>16</b>	<b>Is It Possible That the Metabolic Syndrome Originates in the Perinatal Period?</b>	<b>177</b>
	Perinatal Programming of Appetite Regulatory Centers and Hypothalamic Centers	177
	Insulin and Insulin Receptors in the Brain	178
<b>17</b>	<b>Essential Fatty Acids: Biochemistry and Physiology</b>	<b>181</b>
	Metabolism of EFAs	181
	Dietary Sources of EFAs	183
	Modulators of Metabolism of EFAs	183
	PUFAs and SREBPs	184
	Cholesterol, Saturated Fats, and Trans-fats Interfere with the Activity of $\Delta^6$ and $\Delta^5$ Desaturases	185
	Actions of EFAs and Their Metabolites	188
	Brief Description of Formation of Lipoxins, Resolvins, Neuroprotectin D1 (Protectins), and Maresins	193
	Nitrolipids	194
<b>18</b>	<b>Role of EFAs/PUFAs in Brain Growth and Development and Pathophysiology of the Metabolic Syndrome</b>	<b>201</b>
	PUFAs in Brain Growth and Development	201

RAR-RXR Nuclear Receptors, PUFAs, and Neuronal Growth	202
Interaction among TNF- $\alpha$ , AA/EPA/DHA, and Insulin and Their Role in Neuronal Growth and Synapse Formation	202
PUFAs and Catenin, <i>wnt</i> , and Hedgehog Signaling Pathway in Brain Growth and Development	203
$\beta$ -Catenin- <i>Wnt</i> Signaling and PUFAs	205
Modulation of the Secretion and Function of NMDA, $\gamma$ -Aminobutyric Acid (GABA), Serotonin, and Dopamine by PUFAs	205
Leptin Regulates NPY/AgRP and POMC/CART Neurons and Programs Hypothalamic “Body Weight/Appetite/Satiety Set Point”	209
PUFAs Regulate Leptin, NPY/AgRP, and POMC/CART Neurons and Participate in Programming Hypothalamic “Body Weight/Appetite/Satiety Set Point”	212
PUFAs, Insulin, and Acetylcholine Not Only Interact among Themselves but Are Also Neuroprotective in Nature	215
PUFAs and Insulin Resistance	215
Maternal Diet Influences $\delta\Delta^6$ and $\delta\Delta^5$ Desaturases and Leptin Levels	216
Interaction(s) among Hypothalamic Neuropeptides, Gut, Adipose Tissue, Insulin, Cytokines, and Free Radicals and Its Relevance to the Pathophysiology of the Metabolic Syndrome	217
Hypothalamic Gene Expression Profile in the RYGB Animal Model	218
Increased Phospholipase A <sub>2</sub> Expression after RYGB Surgery and Its Relevance to Suppression of Low-grade Systemic Inflammation in the Obese and Formation of Anti-inflammatory Lipids	219
Expression of Gene for eNOS in RYGB	220
RYGB-induced Weight Loss Is Due to Changes in the Levels of Hypothalamic Neuropeptides and Monoamines	220
What Are the Diagnostic and Prognostic Implications of This Knowledge?	221
Therapeutic Implications	223
PUFAs and Endocannabinoids	224
PUFAs and Type 2 Diabetes Mellitus	224
Hypothalamic PUFAs Regulate Insulin Secretion and Glucose Homeostasis by Influencing ATP-sensitive K <sup>+</sup> Channels	225
Vagus as the Communicator between Gut, Liver, and Hypothalamus	227
<b>19 EFAs/PUFAs and Their Metabolites in Insulin Resistance</b>	<b>240</b>
GLUT-4 in Insulin Resistance	240
Tumor Necrosis Factor Induces Insulin Resistance	242
Caloric Restriction Influences Insulin Signaling Pathway, Antioxidants, <i>daf</i> genes, PTEN, Sirtuins (Silent Mating Type Information Regulation 2 Homologue), and Longevity and Their Relationship to Insulin Resistance	242
PUFAs Can Reduce Insulin Resistance	244
PUFAs, GLUT-4, TNF- $\alpha$ , Anti-oxidants, <i>daf</i> Genes, SIRT1, and PPARs	245
Clinical Implications of the Interactions among PUFAs, <i>daf</i> Genes, PPARs, and Sirtuins	246

<b>20 EFAs/PUFAs and Atherosclerosis</b>	<b>252</b>
Atherosclerosis Is a Systemic Inflammatory Condition	252
Cross-talk among Platelets, Leukocytes, and Endothelial Cells	253
Leukocytes and Atherosclerosis	254
EFAs Modulate Uncoupling Protein-1 Expression	255
Interaction(s) among $\omega$ -3 and $\omega$ -6 Fatty Acids and Trans-fats and Saturated Fats	255
Atheroprotective Actions of $\omega$ -3 and $\omega$ -6 Fatty Acids: How and Why?	259
<b>Index</b>	<b>265</b>